BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
All
Regulatory & Policy
Pharma & GLP-1
Research Pipeline
Industry & Community
Reputational Risks
BSR Insights
Regulatory & Policy · 05 May 2026
FDA schedules July PCAC review for seven peptides as Category 2 compounding restrictions lapse
Twelve peptides — including BPC-157, TB-500, Semax and Epitalon — were removed from the FDA's Category 2 "unsafe to compound" list on 23 April 2026. Seven of them now go before the Pharmacy Compounding Advisory Committee on 23-24 July 2026 for potential addition to the 503A Bulks List. Removal from Category 2 is not the same as authorisation to compound.
Read briefing →